title: [Aclarubicin-related pancreatitis in a child with AML].
authors.forename: S
authors.initials: S
authors.lastname: Adachi
authors.forename: Y
authors.initials: Y
authors.lastname: Akiyama
authors.forename: T
authors.initials: T
authors.lastname: Takimoto
authors.forename: A
authors.initials: A
authors.lastname: Tanizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kiriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: H
authors.initials: H
authors.lastname: Mikawa
mesh_terms: D015250:Aclarubicin; D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D009279:Naphthacenes / Q000008:administration & dosage / Q000009:adverse effects; D010195:Pancreatitis / Q000139:chemically induced*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D009279:Naphthacenes; D003561:Cytarabine; D014750:Vincristine; D015250:Aclarubicin; C015019:enocitabine; D015122:Mercaptopurine